ClinicalTrials.gg
CompletedNCT02262793Updated Oct 13, 2014

Relative Bioavailability of Telmisartan and Dipyridamole After Co-administration Compared to the Bioavailability of Telmisartan or Dipyridamole Alone in Healthy Female and Male Subjects

A Phase 1 interventional study of telmisartan and ASA/ER-DP in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-13.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Study summary

To investigate the relative bioavailability of telmisartan respectively of dipyridamole after concomitant administration of 80 mg telmisartan in Micardis® and 25 mg acetylsalicylic acid (ASA)/200 mg extended release (ER) dipyridamole (DP) in Aggrenox® (Test 1) relative to ER-DP in Aggrenox® alone (Reference 1), respectively relative to telmisartan in Micardis® alone (Reference 2).

To investigate the relative bioavailability of dipyridamole respectively of telmisartan administered as 25 mg ASA/200 mg ER-DP 30 minutes after intake of 80 mg telmisartan (Test 2) relative to dipyridamole in Aggrenox® alone (Reference 1), respectively relative to telmisartan in Micardis® alone (Reference 2).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy females and males according to the following criteria:

    Based upon a complete medical history, including the physical examination, vital signs (BP, HR), 12-lead , clinical laboratory tests

    • No finding deviating from normal and of clinical relevance
    • No evidence of a concomitant disease
  2. Age ≥21 and Age ≤65 years
  3. ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)
  4. Signed and dated written prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation

Exclusion criteria

Exclusion Criteria:

  1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  2. Surgery of gastrointestinal tract (except appendectomy)
  3. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  4. History of relevant orthostatic hypotension, fainting spells or blackouts.
  5. Chronic or relevant acute infections
  6. History of allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  7. Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  8. Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
  9. Participation in another trial with an drug within two months prior to administration or during the trial
  10. Smoker (more than 10 cigarettes/day or 3 cigars/day or 3 pipes/day)
  11. Inability to refrain from smoking on trial days
  12. Alcohol abuse (more than 60 g/day)
  13. Drug abuse
  14. Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  15. Excessive physical activities (within one week prior to administration or during the trial)
  16. Any laboratory value outside the reference range that is of clinical relevance
  17. Inability to comply with dietary regimen of study centre
  18. History of hereditary fructose intolerance
  19. History of any familial bleeding disorder
  20. Veins unsuited for i.v. puncture on either arm (e.g. veins which are difficult to locate, access or puncture, veins with a tendency to rupture during or after puncture, etc.)
  21. Inability to comply with the investigators instructions

    For female subjects:

  22. Pregnancy
  23. Positive pregnancy test
  24. No adequate e.g. oral contraceptives, sterilization, intrauterine device (IUD)
  25. Inability to maintain this adequate contraception during the whole study period
  26. Lactation period
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    telmisartan and ASA/ER-DP (concomitant)

    Drug: telmisartan · Drug: ASA/ER-DP

  • Active comparator
    ASA/ER-DP alone

    Drug: ASA/ER-DP

  • Experimental
    telmisartan and ASA/ER-DP (consecutively)

    Drug: telmisartan · Drug: ASA/ER-DP

  • Active comparator
    telmisartan

    Drug: telmisartan

Interventions

06

What researchers measure

Primary outcomes

  1. AUC0-∞ (area under the concentration time curve in plasma from 0 extrapolated to infinity)

    Time frame: up to 72 hours following drug administration

  2. Cmax (maximum concentration in plasma)

    Time frame: up to 72 hours following drug administration

Secondary outcomes

  1. AUC0-tz (area under the concentration-time curve in plasma over the time interval from 0 to the time of the last quantifiable data point)

    Time frame: up to 72 hours following drug administration

  2. AUCt1-t2 (Area under the concentration time curve in plasma over the time interval t1 to t2)

    Time frame: up to 72 hours following drug administration

  3. tmax (time from dosing to the maximum concentration of the analytes in plasma)

    Time frame: up to 72 hours following drug administration

  4. λz (terminal rate constant in plasma)

    Time frame: up to 72 hours following drug administration

  5. t1/2 (terminal half-life of the analytes in plasma)

    Time frame: up to 72 hours following drug administration

  6. MRTpo (mean residence time of the analyte in the body after p.o. administration)

    Time frame: up to 72 hours following drug administration

  7. CL/F (apparent clearance of the analytes in the plasma after extravascular administration)

    Time frame: up to 72 hours following drug administration

  8. Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)

    Time frame: up to 72 hours following drug administration

  9. Number of subjects with adverse events

    Time frame: up to 8 days after last drug administration

  10. Number of subjects with clinically significant findings in vital signs

    blood pressure, heart rate

    Time frame: up to 8 days after last drug administration

  11. Number of subjects with clinically significant findings in 12 lead ECG

    Time frame: up to 8 days after last drug administration

  12. Number of subjects with clinically significant findings in laboratory tests

    Time frame: up to 8 days after last drug administration

  13. Assessment of tolerability by the investigator on a 4-point scale

    Time frame: up to 8 days after last drug administration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2004 and a primary completion of Jul 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2014
First posted
Oct 13, 2014
Start
May 2004
Primary completionActual
Jul 2004
Last update
Oct 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02262793
Responsible party
Sponsor
First posted
Oct 13, 2014
Start date
May 2004
Primary completion
Jul 2004
Last update
Oct 13, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Aspirin

Start the discussion